Candel's CEO said the company learned on November the 9th that validating the IU assay would take six months, pushing BLA completion to mid-2027. The delay is analytical rather than manufacturing-related, and the CV must consistently stay below 30%. The launch target moves from Q4, 2027 to Q1, 2028.
CADL · Candel Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Candel Therapeutics said it became aware on November the 9th that validation of its potency assay would take six months. The company said the delay is analytical rather than manufacturing-related, and the coefficient of variability must be consistently lower than 30%. Launch is now targeted for Q1, 2028, and the cash runway extends into the second quarter of 2028.
On November 12, 2026, Candel Therapeutics, Inc. entered a new at-the-market agreement with Jefferies LLC for up to $50,000,000 of common stock, after selling approximately $50,000,000 under its 2025 agreement. Jefferies receives a 3.0% commission on gross proceeds.
Candel Therapeutics said aglatimagene achieved a 39% improvement in prostate cancer-specific disease-free survival at 58.0 months median follow-up, plans a BLA submission in the middle of 2027, and paused pancreatic cancer development.
Candel Therapeutics plans to submit aglatimagene’s prostate cancer BLA in the middle of 2027 pending FDA dialogue, while $203.1 million in cash is expected to fund operations into Q2 2028. Third-quarter 2026 net loss widened to $21.9 million from $11.3 million.
CADL’s aglatimogene prostate trial achieved its primary endpoint in December 2024; payer research indicates a median price range of $285,000 for three administrations, though the company said that price was not assured.
Candel Therapeutics said aglatimogene met its phase 3 primary endpoint in localized prostate cancer in December 2024, with no increase in serious adverse events versus placebo. A phase 3 study in second-line non-small cell lung cancer has begun.